Table 2.
Characteristics of the cell lines used in this work.
| Cell Line | Origin | Latency Type | Particularity |
|---|---|---|---|
| B95.8 | Primary infection [31] | Lat III [32] | Deletion 139,724 bp to 151,554 bp: OriLyt—large part of miRNA BART—LF-1, -2, -3 [31,33,34] |
| Jijoye | Endemic Burkitt’s lymphoma [35] | Lat III [36] | No deletion |
| Namalwa | Endemic Burkitt’s lymphoma [37] | Lat I [38] Lat III [36] |
2 copies of EBV genome integrated into the human chromosome [39] |
| P3HR1 | Burkitt’s lymphoma [40] | Lat I [36] Lat II [41] Atypical latency [42] |
Derived from Jijoye—Deletion (33,355 bp to 40,163 bp): EBNA-2, part of EBNA-LP, part of BHLF-1 [34,38,43] |
| Raji | Burkitt’s lymphoma [44] | Lat III [36] Lat I/Lat III (in vitro) [38] |
Two deletions (99,126 bp to 102,118 bp and 163,978 bp to 166,635 bp): EBNA-3C, BZLF2, BARF1, BALF1, BALF2 [45,46] |
| MEC04 | NK/T lymphoma [47] | Lat II [47] | |
| SNK6 | NK/T lymphoma [48] | Lat II [48] | EBNA-2 not expressed [49,50] |